Mary Kay’s Iconic Pink Cadillac Goes Electric with the All-New OPTIQ
24.7.2025 14:00:00 CEST | Business Wire | Press Release
Global cosmetics giant, Mary Kay Inc., today announced a major milestone in its legacy of empowerment: the transformation of its beloved pink Cadillac into a fully electric vehicle (EV). The pink Cadillac OPTIQ made its debut during Mary Kay’s annual Seminar, hosted for the first time in the vibrant city of Charlotte, North Carolina.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250724749681/en/
“For decades, the Mary Kay pink Cadillac has symbolized accomplishment, aspiration, and the power of recognition,” said Ryan Rogers, Chief Executive Officer of Mary Kay. “With the introduction of the all-electric OPTIQ, we’re honoring that iconic legacy while driving into a transformative future—one grounded in our commitment to sustainability and dedication to inspiring and celebrating the achievements of our independent sales force for generations to come.” (Photo Courtesy: Mary Kay Inc.)
The Cadillac OPTIQ is a significant step forward in Mary Kay’s commitment to innovation, environmental responsibility, and meeting expectations of the next generation of both Mary Kay independent sales force members and their customers. The transition from internal combustion to electric symbolizes more than just a vehicle upgrade, it marks a recharged vision for the future of the iconic beauty brand.
“For decades, the Mary Kay pink Cadillac has symbolized accomplishment, aspiration, and the power of recognition,” said Ryan Rogers, Chief Executive Officer of Mary Kay. “With the introduction of the all-electric OPTIQ, we’re honoring that iconic legacy while driving into a transformative future—one grounded in our commitment to sustainability and dedication to inspiring and celebrating the achievements of our independent sales force for generations to come.”
“Our relationship with Mary Kay spans decades and is built on shared values of innovation, empowerment, and excellence,” said Ian Hucker, VP GM Envolve. “As the organization takes bold steps into the future with the transition to an electric vehicle, we are proud to stand beside them, supporting a vision that’s not only sustainable but also deeply inspiring. The pink Cadillac OPTIQ is an exciting step forward, bringing together the performance and luxury you expect from Cadillac with meaningful innovation and purpose-driven impact.”
About The Pink Cadillac OPTIQ:
- OPTIQ retains the instantly recognizable pink pearl exterior, while introducing a sleek, modernized chassis with cutting-edge features. As part of Mary Kay’s commitment to sustainability, the vehicle showcases the company’s dedication to reducing its carbon footprint while continuing to inspire.
- OPTIQ’s exceptional aerodynamic performance enables its EPA-estimated 302-mile driving range1. The revolutionary GM EV Battery Platform and drive units, along with the use of low rolling resistance tires, also play an important role in the impressive range of the vehicle.
- A vented rear spoiler, diffusers, and other sculptural elements enhance aerodynamics at the rear of the vehicle without compromising the striking SUV vehicle design.
- OPTIQ packages interior spaciousness and luxury into a comfortable suite. Illuminated décor and embellishments add to OPTIQ’s unique interior interpretation of Cadillac luxury, while the suite of in-vehicle technology includes features such as the 19-speaker AKG Audio System and Dolby Atmos, creating an intuitive experience.
Did You Know:
- The iconic pink Cadillac was born in 1968 when Mary Kay Ash purchased a Cadillac Coupe De Ville from a Dallas dealership and promptly had it painted to match the pale pink Mary Kay® lip and eye palette. General Motors later named the color Mary Kay Pink Pearl, and the shade is exclusive to Mary Kay.
- Mary Kay has been named the #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World2 by Euromonitor International for three consecutive years, in 2023, 2024, and again in 2025.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty brand in Texas in 1963 with one goal: to enrich women’s lives. That dream has blossomed into a global company with millions of independent sales force members in more than 40 markets. For over 60 years, the Mary Kay opportunity has empowered women to define their own futures through education, mentorship, advocacy, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in preserving our planet for future generations, protecting women impacted by cancer and domestic abuse, and encouraging youth to follow their dreams. Learn more at marykayglobal.com. Find us on Facebook, Instagram, and LinkedIn, or follow us on X.
1 | GM-Estimated range based on development testing and/or analytical projection consistent with SAE J1634 revision 2017- MCT and subject to change prior to production. Actual range may vary based on several factors, including temperature, terrain, battery age, loading and how you use and maintain your vehicle. Visit www.cadillac.com for more information. | ||
2 | “Source Euromonitor International Limited; Beauty and Personal Care 2025 Edition, value sales at RSP, 2024 data” | ||
View source version on businesswire.com: https://www.businesswire.com/news/home/20250724749681/en/
Contacts
Mary Kay Inc. Corporate Communications
marykay.com/newsroom -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fnewsroom.maryk
ay.com%2F&esheet=54295563&newsitemid=20250724749681&lan=en-US&anchor=marykay.com
%2Fnewsroom&index=9&md5=54a9e360c61db9c35de79c6410230bf4
972.687.5332 or media@mkcorp.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom